

*Handwritten:* Ft Shimney Kruger

Specimen Number <b>263-480-2797-0</b>		Patient ID		Control Number CNT31143092	Account Number 31143092	Account Phone Number 212-535-1012	Route 70
Patient Last Name <b>EPSTEIN</b>				Account Address Woodson Merrell			
Patient First Name <b>JEFFREY</b>		Patient Middle		44 E 67th St New York NY 10065			
Age (Y/M/D) 60/08/00		Date of Birth 01/20/53	Sex M	Total Volume			
Patient Address 9 E 71ST ST NEW YORK NY 10065				Additional Information UPIN: A62553			
Date and Time Collected 09/20/13 14:00	Date Entered 09/21/13	Date and Time Reported 09/25/13 15:06ET		Physician Name MERRELL, W	NPI 1023153509	Physician ID MERRELL	

**Tests Ordered**  
NMR LipoProfile; CBC With Differential/Platelet; Comp. Metabolic Panel (14); PE+Interp(Rfx IFE),S; Lyme Ab/Western Blot Reflex; Iron and TIBC; Testosterone,Free+Weakly Bound; Prolactin; DHEA-Sulfate; Homocyst(e)line, Plasma; C-Reactive Protein, Cardiac; Hemoglobin Alc; Prostate-Specific Ag, Serum; TSH; Vitamin D, 25-Hydroxy; Uric Acid, Serum; GGT; Insulin; Ambiguous Test Order; Ferritin, Serum; Request Problem

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
-------	--------	------	-------	--------------------	-----

**NMR LipoProfile**

LDL Particle Number					01
<b>LDL-P</b>	<b>2111</b>	<b>High</b>	nmol/L	<1000	01
			Low	< 1000	
			Moderate	1000 - 1299	
			Borderline-High	1300 - 1599	
			High	1600 - 2000	
			Very High	> 2000	

Lipids					01
<b>LDL-C</b>	<b>NOTES:</b>		mg/dL	<100	01
LDL-C cannot be calculated because triglycerides are > 400 mg/dL.					

Optimal	<	100
Above optimal	100 -	129
Borderline	130 -	159
High	160 -	189
Very high	>	189

<b>HDL-C</b>	<b>30</b>	<b>Low</b>	mg/dL	>=40	01
<b>Triglycerides</b>	<b>993</b>	<b>High</b>	mg/dL	<150	01
<b>Cholesterol, Total</b>	<b>263</b>	<b>High</b>	mg/dL	<200	01
LDL and HDL Particles					01
<b>HDL-P (Total)</b>	<b>28.7</b>	<b>Low</b>	umol/L	>= 30.5	01
<b>Small LDL-P</b>	<b>1548</b>	<b>High</b>	nmol/L	<= 527	01
<b>LDL Size</b>	<b>19.8</b>	<b>Low</b>	nm	> 20.5	01

\*\*\* INTERPRETATIVE INFORMATION \*\*\*

PARTICLE CONCENTRATION AND SIZE

<--Lower CVD Risk Higher CVD Risk-->

LDL AND HDL PARTICLES	Percentile in Reference Population				
HDL-P (total)	High	75th	50th	25th	Low
	>34.9	34.9	30.5	26.7	<26.7

<b>EPSTEIN, JEFFREY</b>	<b>263-480-2797-0</b>	Seq # 5515
-------------------------	-----------------------	------------

09/25/13 15:06 ET

**FINAL REPORT**

Page 1 of 6

This document contains private and confidential health information protected by state and federal law.  
If you have received this document in error, please call 800-631-5250

©2004-13 Laboratory Corporation of America © Holdings  
All Rights Reserved  
DOC1 Ver: 1.49

Pf  
Shirley  
Kroger

Patient Name <b>EPSTEIN, JEFFREY</b>					Specimen Number <b>263-480-2797-0</b>		
Account Number 31143092	Patient ID	Control Number CNT31143092	Date and Time Collected 09/20/13 14:00	Date Reported 09/25/13	Sex M	Age(Y/M/D) 60/08/00	Date of Birth 01/20/53
TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB		

Small LDL-P	Low	25th	50th	75th	High
	<117	117	527	839	>839
LDL Size	<-Large (Pattern A)->		<-Small (Pattern B)->		
	23.0	20.6	20.5	19.0	

Insulin Resistance Score

**LP-IR Score** **100 High** <= 45 01

LP-IR Score is inaccurate if patient is non-fasting. The LP-IR Score combines information from lipoprotein particle concentration and size to give improved assessment of insulin resistance and diabetes risk. Small LDL-P, LDL Particle Size, HDL-Particle, and LP-IR Score have been validated by LipoScience but not cleared by US FDA; the clinical utility of these test results has not been fully established.

INSULIN RESISTANCE MARKER

<--Insulin Sensitive Insulin Resistant-->  
Percentile in Reference Population

Insulin Resistance Score

LP-IR Score	Low	25th	50th	75th	High
	<27	27	45	63	>63

**CBC With Differential/Platelet**

WBC	6.4	x10E3/uL	3.4 - 10.8	02
RBC	5.24	x10E6/uL	4.14 - 5.80	02
Hemoglobin	15.3	g/dL	12.6 - 17.7	02
Hematocrit	43.9	%	37.5 - 51.0	02
MCV	84	fL	79 - 97	02
MCH	29.2	pg	26.6 - 33.0	02
MCHC	34.9	g/dL	31.5 - 35.7	02
RDW	14.3	%	12.3 - 15.4	02
Platelets	269	x10E3/uL	155 - 379	02
Neutrophils	56	%	40 - 74	02
Lymphs	31	%	14 - 46	02
Monocytes	8	%	4 - 12	02
Eos	4	%	0 - 5	02
Basos	1	%	0 - 3	02
Neutrophils (Absolute)	3.6	x10E3/uL	1.4 - 7.0	02
Lymphs (Absolute)	2.0	x10E3/uL	0.7 - 3.1	02
Monocytes (Absolute)	0.5	x10E3/uL	0.1 - 0.9	02
Eos (Absolute)	0.3	x10E3/uL	0.0 - 0.4	02
Baso (Absolute)	0.1	x10E3/uL	0.0 - 0.2	02
Immature Granulocytes	0	%	0 - 2	02
Immature Grans (Abs)	0.0	x10E3/uL	0.0 - 0.1	02

<b>EPSTEIN, JEFFREY</b>	<b>263-480-2797-0</b>	Seq # 5515
-------------------------	-----------------------	------------

09/25/13 15:06 ET

**FINAL REPORT**

Page 2 of 6

This document contains private and confidential health information protected by state and federal law. If you have received this document in error, please call 800-631-5250

©2004-13 Laboratory Corporation of America © Holdings  
All Rights Reserved  
DOC1 Ver: 1.49

*Pt Shimal Kruger*

Patient <b>EPSTEIN, JEFFREY</b>					Specimen Number <b>263-480-2797-0</b>		
Account Number 31143092	Patient ID	Control Number CNT31143092	Date and Time Collected 09/20/13 14:00	Date Reported 09/25/13	Sex M	Age(Y/M/D) 60/08/00	Date of Birth 01/20/53

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
<b>Comp. Metabolic Panel (14)</b>					
<b>Glucose, Serum</b>	<b>103</b>	<b>High</b>	mg/dL	65 - 99	02
BUN	19		mg/dL	8 - 27	02
Creatinine, Serum	0.94		mg/dL	0.76 - 1.27	02
eGFR If NonAfricn Am	88		mL/min/1.73	>59	
eGFR If Africn Am	101		mL/min/1.73	>59	
BUN/Creatinine Ratio	20			10 - 22	
Sodium, Serum	139		mmol/L	134 - 144	02
Potassium, Serum	4.1		mmol/L	3.5 - 5.2	02
Chloride, Serum	98		mmol/L	97 - 108	02
Carbon Dioxide, Total	19		mmol/L	19 - 28	02
Calcium, Serum	10.1		mg/dL	8.6 - 10.2	02
Protein, Total, Serum	7.3		g/dL	6.0 - 8.5	02
Albumin, Serum	4.5		g/dL	3.6 - 4.8	02
Globulin, Total	2.8		g/dL	1.5 - 4.5	
A/G Ratio	1.6			1.1 - 2.5	
Bilirubin, Total	0.6		mg/dL	0.0 - 1.2	02
Alkaline Phosphatase, S	58		IU/L	44 - 102	02
AST (SGOT)	35		IU/L	0 - 40	02
<b>ALT (SGPT)</b>	<b>66</b>	<b>High</b>	IU/L	0 - 44	02
<b>PE+Interp(Rfx IFE), S</b>					
Albumin	4.2		g/dL	3.2 - 5.6	02
Alpha-1-Globulin	0.2		g/dL	0.1 - 0.4	02
Alpha-2-Globulin	0.8		g/dL	0.4 - 1.2	02
Beta Globulin	1.0		g/dL	0.6 - 1.3	02
Gamma Globulin	1.0		g/dL	0.5 - 1.6	02
M-Spike	Not Observed		g/dL	Not Observed	02
Globulin, Total	3.1		g/dL	2.0 - 4.5	
A/G Ratio	1.4			0.7 - 2.0	

Please note: Protein electrophoresis scan will follow via computer, mail, or courier delivery. Interpretation(See Below) The SPE pattern appears essentially unremarkable. Evidence of monoclonal protein is not apparent.

<b>Lyme Ab/Western Blot Reflex</b>					
<b>Lyme IgG/IgM Ab</b>	<b>0.92</b>	<b>High</b>	index	0.00 - 0.90	02
			Negative	<0.91	
			Equivocal	0.91 - 1.09	
			Positive	>1.09	

Note: The CDC currently advises that Western blot testing be performed following all equivocal or positive EIA results. Final diagnosis should include appropriate clinical findings and a positive EIA which is also positive by Western blot.

<b>EPSTEIN, JEFFREY</b>	<b>263-480-2797-0</b>	Seq # 5515
-------------------------	-----------------------	------------

*Dr  
Shirley  
Kroger*

Patient Name <b>EPSTEIN, JEFFREY</b>					Specimen Number <b>263-480-2797-0</b>		
Account Number 31143092	Patient ID	Control Number CNT31143092	Date and Time Collected 09/20/13 14:00	Date Reported 09/25/13	Sex M	Age(Y/M/D) 60/08/00	Date of Birth 01/20/53

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
Lyme Ab Interp., EIA	Equivocal				02
Lyme Ab IgG by WB:					02
IgG P93 Ab.	Absent				02
IgG P66 Ab.	Absent				02
<b>IgG P58 Ab.</b>	<b>Present</b>	<b>Abnormal</b>			02
IgG P45 Ab.	Absent				02
<b>IgG P41 Ab.</b>	<b>Present</b>	<b>Abnormal</b>			02
IgG P39 Ab.	Absent				02
IgG P30 Ab.	Absent				02
IgG P28 Ab.	Absent				02
IgG P23 Ab.	Absent				02
IgG P18 Ab.	Absent				02
Lyme IgG WB Interp.	Negative				02

Positive: 5 of the following  
Borrelia-specific bands:  
18, 23, 28, 30, 39, 41, 45, 58,  
66, and 93.

Negative: No bands or banding  
patterns which do not  
meet positive criteria.

Lyme Ab IgM by WB:					02
IgM P41 Ab.	Absent				02
IgM P39 Ab.	Absent				02
IgM P23 Ab.	Absent				02
Lyme IgM WB Interp.	Negative				02

Note: An equivocal or positive EIA result followed by a negative Western Blot result is considered NEGATIVE. An equivocal or positive EIA result followed by a positive Western Blot is considered POSITIVE by the CDC.

Positive: 2 of the following bands: 23, 39 or 41  
Negative: No bands or banding patterns which do not meet positive criteria.  
Criteria for positivity are those recommended by CDC/ASTPHLD.  
p23=Osp C, p41=flagellin

Note:  
Sera from individuals with the following may cross react in the Lyme Western Blot assays: other spirochetal diseases (periodontal disease, leptospirosis, relapsing fever, yaws, and pinta); connective autoimmune (Rheumatoid Arthritis and Systemic Lupus Erythematosus and also individuals with Antinuclear Antibody); other infections (Rocky Mountain Spotted Fever; Epstein-Barr Virus, and Cytomegalovirus).

Lyme Disease Ab, Quant, IgM	<0.91	index	0.00 - 0.90	02
		Negative	<0.91	

<b>EPSTEIN, JEFFREY</b>		<b>263-480-2797-0</b>	Seq # 5515
-------------------------	--	-----------------------	------------

09/25/13 15:06 ET

**FINAL REPORT**

Page 4 of 6

This document contains private and confidential health information protected by state and federal law.  
If you have received this document in error, please call 800-631-5250

©2004-13 Laboratory Corporation of America © Holdings  
All Rights Reserved  
DOC1 Ver. 1.49

P4  
Shimay  
Kroger

Patient Name					Specimen Number		
<b>EPSTEIN, JEFFREY</b>					<b>263-480-2797-0</b>		
Account Number	Patient ID	Control Number	Date and Time Collected	Date Reported	Sex	Age(Y/M/D)	of Birth
31143092		CNT31143092	09/20/13 14:00	09/25/13	M	60/08/00	01/20/53

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
			Equivocal	0.91 - 1.09	
			Positive	>1.09	

Note: IgM levels may peak at 3-6 weeks post infection, then gradually decline. FDA currently advises that Western Blot testing be performed following all equivocal or positive EIA results. Final diagnosis should include appropriate clinical findings and a positive EIA which is also positive by Western Blot.

**Iron and TIBC**

Iron Bind.Cap. (TIBC)	329		ug/dL	250 - 450	
UIBC	244		ug/dL	150 - 375	02
Iron, Serum	85		ug/dL	40 - 155	02
Iron Saturation	26		%	15 - 55	

**Testosterone, Free+Weakly Bound**

Testosterone, Serum	<u>178</u>	Low	ng/dL	348 - 1197	02
---------------------	------------	-----	-------	------------	----

Prolactin	4.2		ng/mL	4.0 - 15.2	02
-----------	-----	--	-------	------------	----

DHEA-Sulfate	207.7		ug/dL	51.7 - 295.0	02
--------------	-------	--	-------	--------------	----

\*\*Please note reference interval change\*\*

Homocyst(e)ine, Plasma	12.8		umol/L	0.0 - 15.0	02
------------------------	------	--	--------	------------	----

C-Reactive Protein, Cardiac	1.04		mg/L	0.00 - 3.00	02
-----------------------------	------	--	------	-------------	----

Relative Risk for Future Cardiovascular Event  
 Low <1.00  
 Average 1.00 - 3.00  
 High >3.00

Hemoglobin A1c	(5.7)	High	%	4.8 - 5.6	02
----------------	-------	------	---	-----------	----

Increased risk for diabetes: 5.7 - 6.4  
 Diabetes: >6.4  
 Glycemic control for adults with diabetes: <7.0

**Prostate-Specific Ag, Serum**

Prostate Specific Ag, Serum	<u>0.8</u>		ng/mL	0.0 - 4.0	02
-----------------------------	------------	--	-------	-----------	----

Roche ECLIA methodology.

According to the American Urological Association, Serum PSA should decrease and remain at undetectable levels after radical prostatectomy. The AUA defines biochemical recurrence as an initial PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory PSA value 0.2 ng/mL or greater.

<b>EPSTEIN, JEFFREY</b>		<b>263-480-2797-0</b>	Seq # 5515
-------------------------	--	-----------------------	------------

09/25/13 15:06 ET

**FINAL REPORT**

Page 5 of 6

This document contains private and confidential health information protected by state and federal law.

If you have received this document in error, please call 800-631-5250

©2004-13 Laboratory Corporation of America © Holdings

All Rights Reserved

DOC1 Ver: 1.49

*PT  
Shirna  
Krogger*

Patient Name					Specimen Number		
<b>EPSTEIN, JEFFREY</b>					<b>263-480-2797-0</b>		
Account Number	Patient ID	Control Number	Date and Time Collected	Date Reported	Sex	Age(Y/M/D)	Date of Birth
31143092		CNT31143092	09/20/13 14:00	09/25/13	M	60/08/00	01/20/53
TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB		

Values obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.

**TSH** 1.680 uIU/mL 0.450 - 4.500 02

**Vitamin D, 25-Hydroxy** 41.4 ng/mL 30.0 - 100.0 02

Vitamin D deficiency has been defined by the Institute of Medicine and an Endocrine Society practice guideline as a level of serum 25-OH vitamin D less than 20 ng/mL (1,2). The Endocrine Society went on to further define vitamin D insufficiency as a level between 21 and 29 ng/mL (2).

1. IOM (Institute of Medicine). 2010. Dietary reference intakes for calcium and D. Washington DC: The National Academies Press.
2. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. JCEM. 2011 Jul; 96(7):1911-30.

**Uric Acid, Serum**

Uric Acid, Serum 7.1 mg/dL 3.7 - 8.6 02

Please Note: Therapeutic target for gout patients: <6.0

**GGT** 18 IU/L 0 - 65 02

**Insulin** 26.1 High uIU/mL 2.6 - 24.9 02

**Ambiguous Test Order**

Attempts to contact your facility to clarify an ambiguous test order were unsuccessful. Please contact the laboratory to verify the request. Specimens are routinely held for 7 days from date of receipt.

Ambiguous test order: *(fibronogen test n.p.)*  
028240

**Ferritin, Serum** 121 ng/mL 30 - 400 02

**Request Problem**

Test Not Performed. Specimen is lipemic.

TEST: 143257 Testost., % Free+Weakly Bound Panel: 143255

01	S7	LipoScience Inc 2500 Sumner Blvd, Raleigh, NC 27616-3235	Dir: Deanna Franke, PhD
02	RN	LabCorp Raritan 69 First Avenue, Raritan, NJ 08869-1800	Dir: Araceli B Reyes, MD
03	BN	LabCorp Burlington 1447 York Court, Burlington, NC 27215-3361	Dir: William F Hancock, MD

For inquiries, the physician may contact **Branch: 800-631-5250 Lab: 877-547-6837**

<b>EPSTEIN, JEFFREY</b>	<b>263-480-2797-0</b>	Seq # 5515
-------------------------	-----------------------	------------

09/25/13 15:06 ET

**FINAL REPORT**

Page 6 of 6

Laboratory Corporation of America  
Special Chemistry Department  
Raritan, New Jersey


A  
Shimoy  
Eger

### Serum Protein Electrophoresis

Specimen Number: **263480279706** Account No./Name: **31143092-Woodson Merrell**  
Total Protein: **7.3** DID:  
Patient Name: **EPSTEIN, JEFFREY** Account Address 1:  
Patient Id: Account Address 2: **44 E 67th St**  
Birthdate: **20-JAN-1953** Account Address 3: **New York, NY 10065**



SPIFE SPE Split Beta Sample 9 09-23-2013 12:45:08:08



Status: Ok

Fraction	%	g/dL	g/dL Range	
Albumin	58.1	4.2	3.2	5.6
Alpha 1	2.7	0.2	0.1	0.4
Alpha 2	11.2	0.8	0.4	1.2
Beta	13.9	1.0	0.6	1.3
Gamma	14.1	1.0	0.5	1.6
Total		7.3	6.0	8.5

Comment

The SPE pattern appears essentially unremarkable. Evidence of monoclonal protein is not apparent.



LabCorp Raritan  
69 First Avenue  
Raritan, NJ 08869-1800

Phone: 800-631-5250

*Pf Shimoy Kroger*

Specimen Number <b>263-480-2797-1</b>		Patient ID		Control Number CNT31143092	Account Number 31143092	Account Phone Number 212-535-1012	Route 70
Patient Last Name <b>EPSTEIN</b>				Account Address Woodson Merrell			
Patient First Name <b>JEFFREY</b>		Patient Middle Name		44 E 67th St New York NY 10065			
Age (Y/M/D) 60/08/00		Date of Birth 01/20/53	Sex M	Total Volume	Fasting		
Patient Address 9 E 71ST ST NEW YORK NY 10065				Additional Information UPIN: A62553			
Date and Time Collected 09/20/13 14:00	Date Entered 09/25/13	Date and Time Reported 09/26/13 09:05ET		Physician Name MERRELL, W	NPI 1023153509	Physician ID MERRELL,	

Tests Ordered  
FSH and LH; Written Authorization

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
<b>FSH and LH</b>					
LH	5.3		mIU/mL	1.7 - 8.6	01
FSH	4.5		mIU/mL	1.5 - 12.4	01

**Written Authorization**

Written Authorization Received. 01  
 Authorization received from SIGNATURE FILE 09-25-2013  
 Logged by Anca Orban

01	RN	LabCorp Raritan 69 First Avenue, Raritan, NJ 08869-1800	Dir: Araceli B Reyes, MD
For inquiries, the physician may contact <b>Branch: 800-631-5250 Lab: 800-631-5250</b>			

<b>EPSTEIN, JEFFREY</b>		<b>263-480-2797-1</b>	Seq # 5522
-------------------------	--	-----------------------	------------

09/26/13 09:06 ET

**FINAL REPORT**

Page 1 of 1

This document contains private and confidential health information protected by state and federal law.  
 If you have received this document in error, please call 800-631-5250

©2004-13 Laboratory Corporation of America © Holdings  
 All Rights Reserved  
 DOC1 Ver: 1.49

*Pf  
Shma  
Kroyer*

Specimen Number <b>263-480-3235-0</b>	Patient ID	Control Number CMK31143092	Account Number 31143092	Account Phone Number 212-535-1012	Route 70
Patient Last Name <b>EPSTEIN</b>		Account Address Woodson Merrell			
Patient First Name <b>JEFFREY</b>	Patient Middle Name	44 E 67th St New York NY 10065			
Total Volume					
Age (Y/M/D) 60/08/00	Date of Birth 01/20/53	Sex M	Fasting		
Patient Address 9 EAST 71ST ST NEW YORK NY 10065			Additional Information UPIN: A62553		
Date and Time Collected 09/20/13 14:00	Date Entered 09/21/13	Date and Time Reported 09/26/13 09:05ET	Physician Name MERRELL, W	NPI 1023153509	Physician ID

Tests Ordered Lp-PLA2					
--------------------------	--	--	--	--	--

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
Lp-PLA2	137		ng/mL	131 - 199	01
			Low Risk	<200	
			Moderate Risk	200 - 235	
			High Risk	>235	

01 BN LabCorp Burlington Dir: William F Hancock, MD  
1447 York Court, Burlington, NC 27215-3361  
For inquiries, the physician may contact Branch: 800-631-5250 Lab: 800-762-4344

<b>EPSTEIN, JEFFREY</b>	<b>263-480-3235-0</b>	Seq # 5523
-------------------------	-----------------------	------------

*PH  
Shirley  
Kruyer*

Specimen Number <b>263-480-3234-0</b>		Patient ID		Control Number CMJ31143092	Account Number 31143092	Account Phone Number 212-535-1012	Route 70
Patient Last Name <b>EPSTEIN</b>				Account Address Woodson Merrell			
Patient First Name <b>JEFFREY</b>		Patient Middle Name		44 E 67th St New York NY 10065			
[REDACTED]		Total Volume					
Age (Y/M/D) 60/08/00	Date of Birth 01/20/53	Sex M	Fasting	Additional Information  UPIN: A62553			
Patient Address 9 EAST 71ST NEW YORK NY 10021							
Date and Time Collected 09/20/13 00:00	Date Entered 09/21/13	Date and Time Reported 09/25/13 09:05ET	Physician Name MERRELL, W	NPI 1023153509	Physician ID		

Dihydrotestosterone						
Tests Ordered						

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
Dihydrotestosterone	16	Low	ng/dL		01
Reference Range: Adult Male: 30 - 85					

01 ES Esoterix Endocrinology Dir: Samuel Pepkowitz, MD  
4301 Lost Hills Road, Calabasas Hills, CA 91301-5358  
For inquiries, the physician may contact Branch: 800-631-5250 Lab: 800-444-9111

<b>EPSTEIN, JEFFREY</b>		<b>263-480-3234-0</b>	Seq # 5509
-------------------------	--	-----------------------	------------

09/25/13 09:05 ET

**FINAL REPORT**

Page 1 of 1

This document contains private and confidential health information protected by state and federal law.  
If you have received this document in error, please call 800-631-5250

©2004-13 Laboratory Corporation of America © Holdings  
All Rights Reserved  
DOC1 Ver: 1.49

*Shine Kroger*

Specimen Number <b>263-042-7600-0</b>		Patient ID		Control Number CML31143092	Account Number 31143092	Account Phone Number 212-535-1012	Route 70
Patient Last Name <b>EPSTEIN</b>				Account Address Woodson Merrell			
Patient First Name <b>JEFFREY</b>		Patient Middle Name		44 E 67th St New York NY 10065			
[REDACTED]		Total Volume					
Age (Y/M/D) 60/08/00	Date of Birth 01/20/53	Sex M	Fasting No	Additional Information			
Patient Address				Additional Information			
Date and Time Collected 09/20/13 14:00	Date Entered 09/21/13	Date and Time Reported 09/21/13 15:05ET		Physician Name	NPI	Physician ID MERRELL	

Tests Ordered							
Fibrinogen Activity							

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
<b>Fibrinogen Activity</b>	355		mg/dL	193 - 507	01
Specimen was ultracentrifuged before testing to remove extreme lipemia. Results should be interpreted with caution.					

01	RN	LabCorp Raritan 69 First Avenue, Raritan, NJ 08869-1800	Dir: Araceli B Reyes, MD
For inquiries, the physician may contact <b>Branch: 800-631-5250 Lab: 800-631-5250</b>			

<b>EPSTEIN, JEFFREY</b>	<b>263-042-7600-0</b>	Seq # 5484
-------------------------	-----------------------	------------

09/21/13 15:06 ET

**FINAL REPORT**

Page 1 of 1

This document contains private and confidential health information protected by state and federal law.  
If you have received this document in error, please call 800-631-5250

©2004-13 Laboratory Corporation of America © Holdings  
All Rights Reserved  
DOC1 Ver: 1.49

*Dr Shimoy Krogart*

Specimen Number <b>263-480-2784-0</b>		Patient ID		Control Number CMS31143092	Account Number 31143092	Account Phone Number 212-535-1012	Route 70
Patient Last Name <b>EPSTEIN</b>				Account Address Woodson Merrell			
Patient First Name <b>JEFFREY</b>		Patient Middle Name		44 E 67th St New York NY 10065			
[REDACTED]		Total Volume					
Age (Y/M/D) 60/08/00	Date of Birth 01/20/53	Sex M	Fasting	Additional Information			
Patient Address							
Date and Time Collected 09/20/13 00:00	Date Entered 09/21/13	Date and Time Reported 09/21/13 15:05ET		Physician Name	NPI	Physician ID MERRELL	

Tests Ordered							
Ca+PTH Intact							

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
<b>Ca+PTH Intact</b>					
Calcium, Serum	9.6		mg/dL	8.6 - 10.2	01
PTH, Intact	43		pg/mL	15 - 65	01
Intact PTH					01
Interpretation			Intact PTH	Calcium	
Normal			(pg/mL)	(mg/dL)	
Primary Hyperparathyroidism			>65	>10.2	
Secondary Hyperparathyroidism			>65	<10.2	
Non-Parathyroid Hypercalcemia			<65	>10.2	
Hypoparathyroidism			<15	< 8.6	
Non-Parathyroid Hypocalcemia			15 - 65	< 8.6	

01 RN LabCorp Raritan Dir: Araceli B Reyes, MD  
69 First Avenue, Raritan, NJ 08869-1800  
For inquiries, the physician may contact Branch: 800-631-5250 Lab: 800-631-5250

<b>EPSTEIN, JEFFREY</b>	<b>263-480-2784-0</b>	Seq # 5485
-------------------------	-----------------------	------------

09/21/13 15:06 ET

**FINAL REPORT**

Page 1 of 1

This document contains private and confidential health information protected by state and federal law.  
If you have received this document in error, please call 800-631-5250

©2004-13 Laboratory Corporation of America © Holdings  
All Rights Reserved  
DOC1 Ver: 1.49



Laboratory Corporation of America

LabCorp Raritan  
69 First Avenue  
Raritan, NJ 08869-1800

Phone: 800-762-4344

*PA  
Sunday  
Proger*

Specimen Number <b>263-480-3346-0</b>		Patient ID		Control Number CMH31143092	Account Number 31143092	Account Phone Number 212-535-1012	Route 70
Patient Last Name <b>EPSTEIN</b>				Account Address Woodson Merrell			
Patient First Name <b>JEFFREY</b>		Patient Middle Name		44 E 67th St New York NY 10065			
Age (Y/M/D) 60/08/00		Date of Birth 01/20/53	Sex M				
Patient Address				Additional Information			
Date and Time Collected 09/20/13 14:00	Date Entered 09/21/13	Date and Time Reported 09/23/13 09:05ET		Physician Name	NPI	Phys ID MERRELL	

Tests Ordered						
IGF-1						

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
<b>IGF-1</b>					
Insulin-Like Growth Factor I	127		ng/mL	51 - 194	01

01 BN LabCorp Burlington Dir: William F Hancock, MD  
1447 York Court, Burlington, NC 27215-3361  
For inquiries, the physician may contact **Branch: 800-631-5250 Lab: 800-762-4344**

<b>EPSTEIN, JEFFREY</b>	<b>263-480-3346-0</b>	Seq # 5489
-------------------------	-----------------------	------------